Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; email:
Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Annu Rev Med. 2019 Jan 27;70:521-547. doi: 10.1146/annurev-med-112017-091045.
Multiple myeloma is diagnosed in over 100,000 patients each year worldwide, has an increasing incidence and prevalence in many regions, and follows a relapsing course, making it a significant and growing healthcare challenge. Recent basic, translational, and clinical studies have expanded our therapeutic armamentarium, which now consists of alkylating agents, corticosteroids, deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors. New drugs in these categories, and additional agents, including both small and large molecules, as well as cellular therapies, are under development that promise to further expand our capabilities and bring us closer to the cure of this plasma cell dyscrasia.
多发性骨髓瘤每年在全球诊断出超过 100,000 例患者，在许多地区发病率和患病率不断增加，且呈复发性病程，因此成为一个重大且不断增长的医疗保健挑战。最近的基础、转化和临床研究扩大了我们的治疗武器库，现在包括烷化剂、皮质类固醇、去乙酰化酶抑制剂、免疫调节剂、单克隆抗体和蛋白酶体抑制剂。这些类别中的新药以及其他药物，包括小分子和大分子药物以及细胞疗法，正在开发中，有望进一步扩大我们的能力，并使我们更接近治愈这种浆细胞异常。
